as on December 20, 2025 at 2:29 am IST
Day's Low
Day's High
1.09%
Downside
1.95%
Upside
52 Week's Low
52 Week's High
48.58%
Downside
23.78%
Upside
Check Alnylam Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$52.3B
EPS (TTM)
4.9621
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
1237.62
Industry PE ratio
17.123164556962024
PEG Ratio
-0.49
EBITDA
321.0M
Revenue (TTM)
3.2B
Profit Margin
1.36%
Return On Equity TTM
32.72%
Track how Alnylam Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.
Alnylam Pharmaceuticals, Inc. in the last 5 years
Lowest (-115.71x)
September 30, 2024
Industry (17.12x)
December 20, 2025
Today (1237.63x)
December 20, 2025
Highest (166.89x)
September 30, 2025
Today’s Price to Earnings Ratio: 1237.63x
Compare market cap, revenue, PE, and other key metrics of Alnylam Pharmaceuticals, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $52.3B | 181.08% | 1237.62 | 1.36% | |
| BUY | $37.3B | 371.01% | -16.34 | -264.83% | |
| BUY | $114.7B | 92.72% | 31.44 | 31.35% | |
| BUY | $79.4B | 53.93% | 17.95 | 32.13% |
The Alnylam Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Alnylam Pharmaceuticals, Inc. investment value today
Current value as on today
₹1,68,343
Returns
₹68,343
(+68.34%)
Returns from Alnylam Pharmaceuticals, Inc. Stock
₹63,111 (+63.11%)
Dollar Returns*
₹5,231 (+5.23%)
Based on 34 analysts
70.59%
Buy
29.41%
Hold
0.00%
Sell
Based on 34 analysts, 70.59% of analysts recommend a 'BUY' rating for Alnylam Pharmaceuticals, Inc.. Average target price of $491.92
Get share price movements and forecasts by analysts on Alnylam Pharmaceuticals, Inc..
What analysts predicted
18.62%UPSIDE
Target Price
$491.92
Current Price
$400.34
Analyzed by
34 Analysts
Target
$491.92
Alnylam Pharmaceuticals, Inc. target price $491.92, a slight upside of 18.62% compared to current price of $400.34. According to 34 analysts rating.
Investment in Alnylam Pharmaceuticals, Inc. Shares on INDmoney has dropped by -43.15% over the past 30 days, indicating reduced transactional activity.
Time period: to
Search interest for Alnylam Pharmaceuticals, Inc. Stock has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 16 December
Tue, 05:34 PM
-Alnylam Pharmaceuticals enters a corrective phase after a strong run, declining over 20% from its recent peak.
Tue, 05:39 PM
-Alnylam Pharmaceuticals added to Nasdaq 100, seen as undervalued with a fair value estimate of $493.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
![]()
Alnylam Pharmaceuticals, Inc. has shown a positive revenue trend over the last five quarters, with revenue increasing from $500.91 million to $1.24 billion. This represents an average quarterly revenue growth of 19.3%, indicating consistent financial improvement for the company.
Profit Spike
![]()
Alnylam Pharmaceuticals, Inc. has shown a significant improvement in its net profit over the last two quarters. The net profit increased from -66.27 million dollars to 251.08 million dollars, reflecting an average growth of 126.4% per quarter.
Against Peers
![]()
In the last 3 years, Insmed Incorporated has given 779.0% return, outperforming this stock by 713.1%
Against Peers
![]()
In the last 1 year, Insmed Incorporated has given 148.2% return, outperforming this stock by 85.1%
Price Dip
![]()
In the last 1 month, ALNY stock has moved down by -8.3%
| Organisation | Alnylam Pharmaceuticals, Inc. |
| Headquarters | 675 West Kendall Street, Cambridge, MA, United States, 02142 |
| Industry | Health Technology |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Kevin Joseph Fitzgerald Ph.D. | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development |
Dr. Pushkal P. Garg M.D. | EVP of Development & Medical Affairs and Chief Research & Dev. Officer |
Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercial Officer |
Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer |
Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer |
Mr. Bryan Andrew Supran J.D. | Chief Legal Officer |
Dr. Yvonne L. Greenstreet M.B.A., M.D. | CEO & Director |
Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP |
Ms. Christine Regan Akinc | Chief Corporate Communications Officer |
Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board |
Alnylam Pharmaceuticals, Inc. share price today is $400.34 as on at the close of the market. Alnylam Pharmaceuticals, Inc. share today touched a day high of $408.15 and a low of $395.97.
Alnylam Pharmaceuticals, Inc. share touched a 52 week high of $495.55 on and a 52 week low of $205.87 on . Alnylam Pharmaceuticals, Inc. stock price today i.e. is closed at $400.34,which is 19.21% down from its 52 week high and 94.46% up from its 52 week low.
Alnylam Pharmaceuticals, Inc. market capitalisation is $0.05T as on .
Indian investors can start investing in Alnylam Pharmaceuticals, Inc. (ALNY) shares with as little as ₹89.552 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹895.52 in Alnylam Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Alnylam Pharmaceuticals, Inc. share’s latest price of $400.34 as on December 20, 2025 at 2:29 am IST, you will get 0.0250 shares of Alnylam Pharmaceuticals, Inc.. Learn more about
fractional shares .
Alnylam Pharmaceuticals, Inc. stock has given 181.08% share price returns and 21.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?